デフォルト表紙
市場調査レポート
商品コード
966810

緑膿菌による肺障害:2030年までの疫学予測

Pseudomonas Aeruginosa-Induced Lung Injury - Epidemiology Insight - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.26円
緑膿菌による肺障害:2030年までの疫学予測
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、米国、ドイツ、フランス、イタリア、スペイン、英国、日本の主要7ヶ国の緑膿菌による肺障害の疫学と関連市場について調査したもので、疾病の背景と概要、疫学と患者数、現在の治療法、主な専門家の見解、アンメットニーズなどの情報を提供しています。

目次

第1章 主な調査結果

第2章 エグゼクティブサマリー

第3章 疾患の背景と概要

  • イントロダクション
  • 兆候と症状
  • 病態生理学
  • 危険因子
  • 診断

第4章 ペイシェントジャーニー

第5章 疫学と患者数

  • 主な調査結果
  • 前提と根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国
    • 主要7ヶ国における疫学シナリオ
  • 米国
  • 欧州5ヶ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第6章 治療アルゴリズム、現在の治療と医療

  • 治療と管理
  • 治療アルゴリズム

第7章 主な専門家の見解

第8章 アンメットニーズ

第9章 付録

  • 参考文献
  • レポートの調査手法

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in 7MM (2017-2030)
  • Table 2: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in the United States (2017-2030)
  • Table 4: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in Germany (2017-2030)
  • Table 6: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in France (2017-2030)
  • Table 8: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in Italy (2017-2030)
  • Table 10: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in Spain (2017-2030)
  • Table 12: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in Japan (2017-2030)
  • Table 16: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in 7MM (2017-2030)
  • Figure 2: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in the United States (2017-2030)
  • Figure 4: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in Germany (2017-2030)
  • Figure 6: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in France (2017-2030)
  • Figure 8: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in Italy (2017-2030)
  • Figure 10: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in Spain (2017-2030)
  • Figure 12: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology in Japan (2017-2030)
  • Figure 16: Pseudomonas Aeruginosa-Induced Lung Injury Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report

目次
Product Code: DIEI1085

DelveInsight's 'Pseudomonas Aeruginosa-Induced Lung Injury - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Pseudomonas Aeruginosa-Induced Lung Injury epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Pseudomonas Aeruginosa-Induced Lung Injury Understanding

The DelveInsight Pseudomonas Aeruginosa-Induced Lung Injury epidemiology report gives a thorough understanding of the Pseudomonas Aeruginosa-Induced Lung Injury by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Pseudomonas Aeruginosa-Induced Lung Injury in the US, Europe, and Japan. The report covers the detailed information of the Pseudomonas Aeruginosa-Induced Lung Injury epidemiology scenario in seven major countries (US, EU5, and Japan).

Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology Perspective by DelveInsight

The Pseudomonas Aeruginosa-Induced Lung Injury epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Pseudomonas Aeruginosa-Induced Lung Injury epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Pseudomonas Aeruginosa-Induced Lung Injury epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Pseudomonas Aeruginosa-Induced Lung Injury Detailed Epidemiology Segmentation

The Pseudomonas Aeruginosa-Induced Lung Injury epidemiology covered in the report provides historical as well as forecasted Pseudomonas Aeruginosa-Induced Lung Injury epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Pseudomonas Aeruginosa-Induced Lung Injury report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Pseudomonas Aeruginosa-Induced Lung Injury report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology Report and Model provide an overview of the risk factors and global trends of Pseudomonas Aeruginosa-Induced Lung Injury in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Pseudomonas Aeruginosa-Induced Lung Injury in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Pseudomonas Aeruginosa-Induced Lung Injury
  • The report provides the segmentation of the Pseudomonas Aeruginosa-Induced Lung Injury epidemiology

Report Highlights:

  • 11-Year Forecast of Pseudomonas Aeruginosa-Induced Lung Injury epidemiology
  • 7MM Coverage
  • Total Cases of Pseudomonas Aeruginosa-Induced Lung Injury
  • Total Cases of Pseudomonas Aeruginosa-Induced Lung Injury according to segmentation
  • Diagnosed cases of Pseudomonas Aeruginosa-Induced Lung Injury

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Pseudomonas Aeruginosa-Induced Lung Injury ?
  • What are the key findings pertaining to the Pseudomonas Aeruginosa-Induced Lung Injury epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Pseudomonas Aeruginosa-Induced Lung Injury across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Pseudomonas Aeruginosa-Induced Lung Injury ?
  • What are the currently available treatments of Pseudomonas Aeruginosa-Induced Lung Injury ?

Reasons to buy:

  • The Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Pseudomonas Aeruginosa-Induced Lung Injury market
  • Quantify patient populations in the global Pseudomonas Aeruginosa-Induced Lung Injury market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Pseudomonas Aeruginosa-Induced Lung Injury therapeutics in each of the markets covered
  • Understand the magnitude of Pseudomonas Aeruginosa-Induced Lung Injury population by its epidemiology
  • The Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Pseudomonas Aeruginosa-Induced Lung Injury

3. Pseudomonas Aeruginosa-Induced Lung Injury : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Pseudomonas Aeruginosa-Induced Lung Injury Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Pseudomonas Aeruginosa-Induced Lung Injury Treatment and Management
  • 6.2. Pseudomonas Aeruginosa-Induced Lung Injury Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report